. Although their etiology remains unclear, it has been shown that production of proinflammatory cytokines by infiltrating activated CD4 ϩ T cells and macrophages plays a critical role in the pathogenesis of IBD (2, 4, 10, 13).
INFLAMMATORY BOWEL DISEASES (IBDs), such as Crohn's disease and ulcerative colitis, are chronic inflammatory diseases characterized by massive infiltration of activated effector-memory CD4 ϩ T cells, macrophages, and dendritic cells in the inflamed mucosa (3, 24) . Although their etiology remains unclear, it has been shown that production of proinflammatory cytokines by infiltrating activated CD4 ϩ T cells and macrophages plays a critical role in the pathogenesis of IBD (2, 4, 10, 13) .
It is well known that the activation of CD4 ϩ T cells requires two distinct signals: signal 1 derived from the interaction between the T cell receptor (TCR) and peptide-major histocompatibility complex (MHC), and signal 2, the costimulatory signal, derived from the interaction between costimulatory molecules of CD28 family on CD4 ϩ T cells and their ligands of the B7 family on antigen-presenting cells (APC) (7, 8, 16) . In addition to the CD28/B7 family pathway (27, 28) , accumulating evidence shows that many other costimulatory systems, such as the TNF-␣/TNF-␣ receptor family pathway, are also involved in the pathogenesis of IBDs and animal models of chronic colitis (18, 21, 26, 29) . NKG2D was first shown as a novel costimulatory molecule expressed on NK cells, which was also demonstrated to be expressed on CD8
ϩ T cells, ␥␦ T cells, and NKT cells that have cytotoxic activity (23, 25) . In CD8 ϩ T cells, NKG2D is expressed on activated effector-memory, but not resting naive, CD8 ϩ T cells. The ligands of NKG2D are poorly expressed on normal cells but are upregulated on stressed, transformed, or infected cells (23, 25) . To date, it has been reported that mouse NKG2D ligands include the retinoic acid early inducible (Rae)-1 family of proteins (6) , the minor histocompatibility antigen H60 (20) , and murine UL-16-binding protein-like transcript (Mult)-1 glycoprotein (5) . It has been demonstrated that the activation via NKG2D receptor can enhance negative signals by MHC class I-specific NK cell inhibitory receptors (9, 15) .
Although it had been believed that both human and mouse CD4 ϩ T cells do not express NKG2D, recent studies have suggested that NKG2D expression could be observed in a fraction of CD4 ϩ T cells residing in the peripheral blood and synovial tissue from patients with rheumatoid arthritis (12) . To characterize the role of NKG2D molecule expressed on colitogenic CD4 ϩ effector-memory T cells in the development of colitis, we utilized a Th1-type CD4 ϩ T-cell-mediated Crohn's disease-like colitis model induced in SCID mice by adoptive transfer of CD4 ϩ
CD45RB
high T cells (27) . We here demonstrate that the lamina propria (LP) CD4 ϩ
CD44
high memory T cells in inflamed mucosa express NKG2D. Furthermore, we show that neutralizing anti-mouse NKG2D MAb suppressed the development of colitis.
MATERIALS AND METHODS
Animals. Six-to 8-wk-old female C.B-17 SCID mice and BALB/c mice were purchased from Japan Clea (Tokyo, Japan). Mice were maintained under specific pathogen-free conditions in the Animal Care Facility at Tokyo Medical and Dental University. Donors and littermate recipients were used at 6 -12 wk of age. All experiments were approved by the regional animal study committees.
Antibodies. The anti-murine NKG2D MAb (HMG2D, hamster IgG) was generated by immunizing an American hamster with mouse NKG2D-Fc fusion protein (R&D Systems, Minneapolis, MN). This MAb inhibited the binding of NKG2D-Fc to Rae-1␤ transfectants and blocked the killing of Rae-1␤ transfectants by NK cells but did not activate NK cells in vitro or deplete NK cells in vivo. We confirmed that this activity of HMG2D was comparable to another clone of anti-NKG2D MAb, CX5 (17) (data not shown). The following MAbs were obtained from BD Pharmingen (San Diego, CA) and used for purification of cell populations and flow cytometric analysis: Fc␥R (CD16/CD32)-blocking MAb (2.4G2); FITC-, phycoerythrin (PE)-, and phycoerythrin-cyanin5 (PECy5)-conjugated anti-mouse CD4 (RM4-5); FITC-conjugated anti-mouse CD3 (145-2C11); FITC-conjugated anti-mouse CD45RB (16A); FITC-conjugated anti-mouse CD11b (M1/70); FITC-conjugated anti-mouse CD11c (HL3); FITCconjugated anti-mouse DX5 (DX5); APC-conjugated anti-mouse CD28 (37.51); FITC-conjugated anti-mouse inducible T-cell costimulator (ICOS) (C398.4); FITC-conjugated anti-mouse PD-1 (RMP1-30); PE-conjugated streptavidin; biotin-conjugated rat IgG2; PEconjugated mouse IgG; and PE-conjugated rat IgG.
In vivo experimental design. Colitis was induced in SCID mice by adoptive transfer of CD4 ϩ CD45RB high T cells as previously described (27) . CD4 ϩ T cells were isolated from splenic mononuclear cells from BALB/c mice by using the anti-CD4 (L3T4) MACS magnetic separation system (Miltenyi Biotec, Auburn, CA) according to the manufacturer's instruction. Enriched CD4 ϩ T cells were then labeled with PE-conjugated anti-mouse CD4 MAb (RM4-5) and FITC-conjugated anti-CD45RB MAb (16A) and sorted into CD45RB high (highest staining 30%) and CD45RB low (lowest staining 30%) fractions on a FACS Vantage (Becton Dickinson, Sunnyvale, CA). Each SCID mouse was injected with 200 l ip of PBS containing 3 ϫ 10 5 cells of CD4 ϩ CD45RB high T cells. These mice were then administered with 250 g ip of anti-NKG2D MAb in 250 l PBS three times per week, starting at the day of T cell transfer, over a period of 7 wk in the preventive protocol. An equivalent amount of control hamster IgG (Sigma-Aldrich, St. Louis, MO) was administered in control mice. Negative control SCID mice were also transferred with a mixture of 3 ϫ 10 5 CD4 ϩ CD45RB high T cells and 3 ϫ 10 5 CD4 ϩ CD45RB low T cells. Disease monitoring and clinical scoring. Mice were weighed and monitored for appearance and signs of soft stool and diarrhea once a week. Clinical score (27) was assessed at 7-8 wk after T cell transfer as the sum of three parameters as follows: hunching and wasting, 0 or 1; colon thickening, 0 -3 (0, no colon thickening; 1, mild thickening; 2, moderate thickening; 3, extensive thickening); and stool consistency, 0 -3 (0, normal beaded stool; 1, soft stool; 2, diarrhea; 3, gross bloody stool).
Histological examination. Tissue samples were fixed in 6% phosphate-buffered formalin. Paraffin-embedded sections (5 m) were stained with hematoxylin and eosin. Three tissue samples from the proximal, middle, and distal parts of the colon were prepared. The sections were analyzed without prior knowledge of the type of treatment. The area most affected was graded by the number and severity of lesions. The mean degree of inflammation in the colon was calculated via a modification of a previously described scoring system (19) .
Immunohistochemistry. For immunohistochemistry, colonic samples were snap-frozen in liquid nitrogen and stored at Ϫ80°C. Cryostat sections (5 m) were fixed in 4% paraformaldehyde and detection of mouse CD4 and NKG2D was performed by the avidin-biotin complex method. Briefly, after blocking, the sections were incubated with primary rat anti-mouse NKG2D MAb (clone 191004, R&D Systems) and goat anti-mouse CD4 MAb (AF554, R&D Systems), followed by biotin-conjugated goat anti-rat IgG (1:200, Vector Laboratories, Burlingame, CA) and biotin-conjugated rabbit anti-goat IgG (1:200, Vector Laboratories). The deposition of the biotin on tissue sections was detected by streptavidin-biotinylated horseradish peroxidase complex (Vectastain ABC kit, Vector) and diaminobenzidine. Then the sections were counterstained with hematoxylin.
To assess the colocalization of CD4 and NKG2D on colitic LP CD4 ϩ T cells, we further performed an immunofluorescent staining experiment. Sections were incubated with rat anti-mouse NKG2D MAb (clone 191004) and goat anti-mouse CD4 MAb (AF554), followed by biotin-conjugated goat anti-rat IgG and amino acid polymer conjugated with rabbit anti-goat IgG and peroxidase (NICHIREI Bioscience, Tokyo, Japan). The samples were then incubated with Alexa 488-conjugated tyramide at a 1:100 dilution (Molecular Probes, Eugene, OR) for detection of CD4 and streptavidinAlexa Fluor 594 conjugate (Molecular Probes) for detection of NKG2D. Cell nuclei were counterstained with DAPI (Molecular Probes). Stained sections were examined by a BioZERO BZ8000 (KEYENCE, Osaka, Japan).
Preparation of LP lymphocytes and splenocytes. For the isolation of LP lymphocytes from the colon, the entire length of intestine was opened longitudinally, washed with PBS, and cut into small pieces. The dissected mucosa was incubated two times with Ca 2ϩ -and Mg 2ϩ -free Hanks' balanced salt solution containing 1 mM dithiothreitol (Sigma-Aldrich) for 30 min each to remove mucus. The supernatants containing intraepithelial cells and epithelial cells were removed. Collected tissues were treated with 3 mg/ml collagenase A (Worthington Biomedical, Freehold, NJ) and 0.01% DNase (Worthington) in RPMI 1640 medium for 2 h. The cells were pelleted two times through a 40% isotonic Percoll solution and then further purified by Ficoll-Hypaque density gradient centrifugation (40%/75%). LP CD4 ϩ T cells were obtained by positive selection via the anti-CD4 (L3T4) MACS magnetic separation system. The cells were Ͼ95% CD4 ϩ when analyzed by flow cytometry. Splenic mononuclear cells were obtained from the same animals by mechanical dissociation of the spleen followed by Ficoll-Hypaque density gradient centrifugation.
Flow cytometry. Isolated LP mononuclear cells or splenocytes were preincubated with Fc␥R-blocking MAb (2.4G2) for 20 min, followed by incubation with FITC-, PE-, or biotin-labeled MAb for 30 min on ice. Biotinylated antibodies were detected with PE-or CyChromestreptavidin. Standard two-or three-color flow cytometric analyses were obtained by use of the FACS Calibur using CellQuest software. Background fluorescence was assessed by staining with control irrelevant isotype-matched MAbs.
Quantitative RT-PCR. Whole colon from colitic SCID mice and age-matched normal BALB/c mice were opened longitudinally, washed, and cut into pieces, then homogenized three times by homogenizer. Each cell population of LP cells from colitic mice was isolated by the anti-CD4, CD11b, or CD11c MACS magnetic separation (Miltenyi Biotec). Colonic intestinal epithelial cells (IECs) were also isolated as previously described (11) . Total RNA was extracted using ISOGEN reagent (Nippon Gene, Tokyo, Japan). Aliquots of 3 g of total RNA were used for complementary DNA synthesis in 14 l of reaction volume by using random primers. One l of complementary DNA was amplified with 12.5 l of SYBR Green PCR master mix (Qiagen, Hilden, Germany) in a 25-l reaction volume. Sense and antisense primers for the amplification of each gene were as follows: sense H60, 5Ј-GTGTGATGACGATT-TGTTGAG-3Ј and antisense H60, 5Ј-ATTGATGGATTCTGGGC-CATA-3Ј; sense Mult-1, 5Ј-CTCATAGGAACAGCATGA-3Ј and an- tisense Mult-1 5Ј-TCCTGTGAAATGTTTGTC-3Ј; sense isoforms of retinoic acid early transcript 1 (Rae-1) molecules (Rae-1␣ϳ␦), 5Ј-ATAATGGATCCATGGCCAAGGCAGCAGTGACCAA-3Ј and antisense Rae-1␣ϳ␦, 5Ј-ATATTATAGCGGCCGCTCACATCG-CAAATGCAAATGCAAATAAT-3Ј; and sense glyceraldehyde-3-phosphate dehydrogenase (G3PDH), 5Ј-TGAAGGTCGGTGTGAA-CGGATTTGGC-3Ј and antisense G3PDH, 5Ј-CATGTAGGC-CATGAGGTCCACCAC-3Ј. Analysis was performed on Applied Biosystems 7500 real-time PCR system (Applied Biosystems, Foster City, CA). mRNA level of each ligand was normalized by the corresponding level of G3PDH mRNA.
Cytokine production assay. To measure cytokine production, LP CD4 ϩ T cells (1 ϫ 10 5 ) were cultured in 200 l of culture medium at 37°C in a humidified atmosphere containing 5% CO2 in 96-well plates (Costar, Cambridge, MA) precoated with 5 g/ml of hamster anti-mouse CD3ε MAb (145-2C11, BD Pharmingen) and 2 g/ml of hamster anti-mouse CD28 MAb (37.51, BD Pharmingen) in PBS overnight at 4°C. Culture supernatants were collected after 48 h of culture and assayed for cytokine production. Cytokine concentrations were measured by mouse Cytokine CBA kit (BD Biosciences, San Jose, CA) per the manufacturer's recommendation.
Statistical analysis. The results were expressed as means Ϯ SE. Groups of data were compared by Mann-Whitney U-test. Differences were considered to be statistically significant when P Ͻ 0.05.
RESULTS

Expression of NKG2D in CD4
ϩ CD45RB high T cell-transferred SCID mice. To investigate whether interactions between NKG2D and its ligands are involved in the development of chronic colitis, we used a murine model of chronic colitis induced in C. (17) , contained substantial number of DX5 ϩ cells (Fig. 1, top) 
CD25
Ϫ T cells contained substantial numbers of CD44 high memory T cells along with CD44 low naive T cells ( Fig. 1, bottom) . Thus we decided to use CD4 ϩ CD45RB high T cells as donor cells to assess the possible role of NKG2D expression by conventional CD4 ϩ T cells in the development of colitis, so as to exclude the involvement of NKT cells.
After adoptive transfer of CD4 ϩ CD45RB high cells, the recipient mice manifested weight loss from 3 wk after transfer and clinical symptoms of colitis such as diarrhea with increased mucus in the stool, anorectal prolapse, and hunched posture by 6 wk (data not shown). The colons from these mice were enlarged and had a greatly thickened wall due to severe colonic inflammation ( Fig. 2A, left) . In contrast, when transferred with a mixture of CD4 ϩ
CD45RB
high and CD4 ϩ CD45RB low cells, the recipient mice did not develop colitis at all as well as control BALB/c mice ( Fig. 2A, left) .We then examined the expression of CD4 and NKG2D in this model by immunohistochemistry. Colonic samples were obtained from colitic SCID mice transferred with CD4 
high and CD4 ϩ CD45RB low cells at 6 wk after the transfer, and agematched BALB/c mice as a control. Figure 2A shows that CD4 ϩ T cells were markedly increased in the inflamed mucosa of colitic SCID mice transferred with CD4 ϩ CD45RB high T cells ( Fig. 2A, middle) , but not in noncolitic SCID mice transferred with CD4 ϩ CD45RB high and CD4 ϩ CD45RB low T cells or normal mice. The majority of CD4 ϩ T cells in colitic SCID mice located in the LP and submucosa, but some of the cells appeared to locate also in the tunica muscularis and subserosa. Of note, in colitic mice, the distribution of NKG2D ϩ cells were scattered within the location of CD4 ϩ T cells ( Fig. 2A, right) , suggesting that NKG2D was expressed by a part of colitic CD4
ϩ LP T cells. In contrast, a small number of CD4 ϩ T cell were indeed found in the LP of noncolitic SCID mice transferred with CD4 ϩ CD45RB high and CD4 ϩ CD45RB low T cells and in normal mice, but expression of NKG2D could never be detected on these normal LP CD4 ϩ T cells ( Fig. 2A, middle and right) . To further confirm that NKG2D is expressed on CD4 ϩ T cells in colitic LP, we performed a double-staining experiment by fluorescent immunostaining. As shown in Fig. 2B, NKG2D was surely expressed by a part of CD4 ϩ T cells in colitic mice. In contrast, a small number of CD4 ϩ T cell showed scattered distribution in the LP of noncolitic SCID or normal BALB/c mice, but NKG2D was not detected in these mice.
To further confirm the expression of NKG2D on CD4 ϩ T cells in colitic mice, we next performed two-color flow cytom- etry analysis. In the colitic samples, NKG2D expression on CD4 ϩ T cells was significantly increased compared with that in normal mice (Fig. 3, A and B) . Although it has been reported that murine NKG2D molecule is usually expressed on DX5 ϩ NK or NKT cells (23, 25) , DX5 ϩ cells could not be detected on cells isolated from colonic tissues through conventional DTT/ collagenase treatment (Fig. 3A) . In the spleen of colitic mice, a significantly increased proportion of CD4 ϩ T cells coexpressed NKG2D, which was not observed in normal mice (Fig. 3, A  and B) . Interestingly, we detected DX5 ϩ cells in the spleen of both colitic and normal mice, where we found that almost all DX5 ϩ cells expressed NKG2D with high intensity (Fig. 3, A  and B) .
Correlation between CD4 ϩ NKG2D ϩ T cells and other costimulatory molecules. It has been recently reported that both CD4 ϩ T cells and CD8 ϩ T cells in the peripheral blood or the synovial tissue of patients with rheumatoid arthritis do not express CD28 but express NKG2D (12) , indicating that NKG2D can function as a complementary molecule of other CD28 family molecules, such as CD28, ICOS, and PD-1. To address this, we assessed phenotypic correlation between these CD28 family molecules on CD4 ϩ T cells using threecolor flow cytometry. Since normal splenic CD4 ϩ T cells do not express NKG2D (Fig. 3, A and B (Fig. 4A) . This was statistically confirmed by assessing the mean fluorescence intensity (MFI) of NKG2D expression (Fig. 4B, left) . In contrast, ICOS and PD-1 molecules were markedly upregulated on colitic CD4 ϩ NKG2D Ϫ and CD4 ϩ NKG2D ϩ cells but were not on normal CD4 ϩ NKG2D Ϫ cells (Fig. 4, A and B) . The results indicated that NKG2D expression is not associated with other representative T cell costimulatory molecules.
Expression of NKG2D ligands in the colon of CD4
ϩ CD45RB high T cell-transferred SCID mice. To clarify the expression of NKG2D ligands in the colon, we next conducted quantitative real-time PCR analysis using whole colonic tissues from colitic mice or age-matched BALB/c mice. This quantitative PCR analysis revealed that mRNA expression of H60 was significantly increased in colitic colon samples compared with that in normal colon samples (Fig. 5A) . In contrast, mRNA expression of Mult-1 and Rae-1 was not significant in colitic colon samples compared with that in normal colon samples (Fig. 5A) . Because of the limitation of recovered cell number of immune cells from normal colon samples, we isolated IECs and LP CD4 ϩ , CD11b ϩ , and CD11c ϩ cells only from the colon of colitic mice to evaluate which NKG2D ligand is expressed in each cell population of colitic mice. As shown in Fig. 5B , H60 mRNA was expressed in every population, but was significantly increased in CD11c ϩ cells compared with that in other populations (Fig. 5B, top) . Mult-1 mRNA was expressed exclusively in CD11c ϩ cells (Fig. 5B,  middle) . Rae-1 mRNA in CD11c ϩ cells was significantly increased compared with that in IECs and CD4 ϩ T cell populations, indicating that the major population expressing NKG2D ligands is CD11c ϩ dendritic cells rather than IECs in colitic mice. ϩ NKG2D Ϫ and CD4 ϩ NKG2D ϩ subpopulation are compared by flow cytometry. Data are shown as mean Ϯ SE of 6 mice in each group. *P Ͻ 0.05; n.s., not significant.
Administration of neutralizing anti-NKG2D MAb prevents the development of colitis. The expression of NKG2D on the infiltrating LP CD4
ϩ T cells and expression of NKG2D ligands in the colitic LP suggested a possible involvement of NKG2D signaling pathway in the pathogenesis of chronic colitis. Thus, to explore the contribution of NKG2D signaling pathway in chronic colitis, nondepleting and neutralizing anti-NKG2D MAb (HMG2D) were administered to the recipient SCID mice transferred with CD4 ϩ CD45RB high T cells started from the day of transfer and then three times a week for 7 wk. As shown in Fig. 6A , control IgG-treated mice manifested progressive weight loss (wasting disease) from 3 wk after transfer. These mice had diarrhea with increased mucus in the stool, anorectal prolapse, and hunched posture by 5-6 wk after transfer. In contrast, anti-NKG2D MAb-treated mice appeared healthy with gradual increase of body weight, and no diarrhea was observed throughout the whole period of observation (Fig. 6A) . At 7 wk after transfer, the colon of control IgG-treated mice was enlarged and had a greatly thickened wall, which was not observed in the anti-NKG2D MAb-treated mice or mice transferred with CD4 ϩ CD45RB high and CD4 ϩ CD45RB low T cells (Fig. 6B) . In addition, enlargement of the spleen and mesenteric lymph nodes were also evident in control IgG-treated mice, but not in anti-NKG2D MAb-treated mice (Fig. 6B) . A comprehensive assessment of colitis by clinical scores showed a clear difference between control IgG-treated mice and anti-NKG2D MAb-treated mice (Fig. 6C) .
Histological examination showed prominent epithelial hyperplasia with glandular elongation with a massive infiltration of mononuclear cells in the LP in the colon of control IgGtreated mice (Fig. 6D) . In contrast, inflammation was mostly abrogated and only few mononuclear cells were observed in the LP of the colon from anti-NKG2D MAb-treated mice and in mice transferred with CD4 ϩ
CD45RB
high and CD4 ϩ CD45RB low T cells (Fig. 6D) . This difference was also confirmed by histological scoring of multiple colon sections, which was 5.2 Ϯ 1.1 in the control rat IgG-treated mice, 2.2 Ϯ 0.8 in anti-NKG2D MAb-treated mice, and 1.6 Ϯ 0.6 in mice transferred with CD4 ϩ CD45RB high and CD4 ϩ CD45RB low T cells (P ϭ 0.01) (Fig. 6E) . A further quantitative evaluation of CD4 ϩ T cell infiltration was done by isolating LP mononuclear cells from resected colons. Only a few CD4 ϩ T cells were recovered from the colonic tissue of anti-NKG2D MAb-treated mice and mice transferred with CD4 ϩ CD45RB high and CD4 ϩ CD45RB low T cells compared with control IgG-treated mice (Fig. 6F) . Furthermore, the number of CD4 ϩ splenocytes from control IgG-treated mice was significantly increased compared with that from age-matched normal BALB/c mice (data not shown). In contrast, the number of CD4 ϩ splenocytes from anti-NKG2D MAb-treated mice was significantly less than that from control IgG-treated mice (data not shown).
We also examined the cytokine production by LP CD4 
DISCUSSION
In the present study, we demonstrated that NKG2D signaling pathway is critically involved in the development of CD4 (Fig. 1 ).
Although they demonstrated that CD4 ϩ CD25 Ϫ donor cells did not express NKG2D before transfer, it remained possible that NKG2D expression could be inducible on activated NKT cells rather than on activated conventional CD4 ϩ T cells especially in case of mouse models (30) . In contrast, we used CD4 ϩ CD45RB high T cells as donor cells, which were characterized to have a cell-surface phenotype of DX5 Ϫ CD44 low , whereas NKT cells were DX5 ϩ CD44 high (Fig.  1) . Thus we believe that NKG2D was solely induced on donor conventional CD4 ϩ cells after transfer in our colitis model. Interestingly, their group showed that anti-NKG2D MAb (CX5) treatment significantly decreased histological score in the colon but did not prevent the wasting disease, compared with control IgG-treated mice. In contrast, however, we here showed that our anti-NKG2D MAb (HMG2D) treatment ameliorated both the histological score and the wasting disease, although the protocol was quite similar except the phenotype of transferred donor cells (CD4 ϩ
CD25
Ϫ vs. CD4 ϩ CD45RB high ). Notably, although the numbers of the donor cells used in these two studies were exactly the same, the kinetic of the development of colitis in control-IgG-treated SCID mice transferred with CD4 ϩ
Ϫ T cells in Kjellev's preventive protocol (17) was obviously more rapid (3 wk of experimental period) compared with those transferred with CD4 ϩ CD45RB high T cells in our protocol (7 wk of experimental period). Although there are several explanations for the discrepancy, including differences in the status of Helicobacter hepaticus infection, the type of animal model, the type of blocking agents, and dosing regimens used, further studies will be needed to address this issue.
In this study, we also demonstrated using whole colonic samples by quantitative real-time RT-PCR analysis that NKG2D ligands were also expressed in colonic tissues in both colitic mice and normal mice. Expectedly, mRNA expression of H60 was significantly increased in colitic colon samples compared with that in normal colon samples, although no significant change was observed in mRNA expression of Mult-1 and Rae-1 between colitic and normal samples. This indicates a possibility that NKG2D signaling pathway modulates the development of chronic colitis and also tunes the degree of colitis.
Recent human studies have demonstrated that not only MICA, which is one of NKG2D ligands in humans, is markedly upregulated on cell surface of inflammatory IECs but also CD8 ϩ NKG2D ϩ intestinal epithelial lymphocytes (IELs) are significantly increased in patients with active celiac disease (14, 22) , suggesting a possible contribution to the pathogenesis of celiac disease due to IEL-mediated damage of IECs by NKG2D-MICA interaction. Furthermore, Allez and colleagues (1) have very recently reported that MICA and NKG2D expression is significantly increased on IECs and LP CD4 ϩ T cells, respectively, in inflamed mucosa of active Crohn's disease. Although all these studies in humans focused on MICA expression in inflamed IECs, interestingly, we found that NKG2D ligands were mainly expressed in CD11c ϩ dendritic cells rather than IECs in inflamed mucosa of colitic SCID mice. Collectively, in our system, it is likely that NKG2D signaling pathway is critically involved in the interactions between T cells and APCs (especially CD11c ϩ dendritic cells) rather than IECs in intestinal mucosal immune system of chronic colitis. However, it remains unclear which ligand of NKG2D plays the dominant role in the pathogenesis of our colitic model. Further studies will be needed to address this issue.
In summary, our present findings suggest that the regulation of NKG2D signaling pathway may be of a key importance in successful treatment of chronic colitis, and targeting of NKG2D-expressing pathogenic CD4 ϩ T cells may be a useful strategy for the treatment of Th1-mediated chronic intestinal inflammation such as Crohn's disease.
